Autologous and allogeneic CAR T cell therapies led by BCMA lead to profound and durable responses in heavily pre-treated multiple myeloma patients with a low incidence of severe cytokine release syndrome and neurotoxicity.
According to Yi Lin, in the near future we will no longer be limited by trial criteria for CAR T-cells. For example, the FDA has granted priority review designation to a biologics license application for idecabtagene vicleucel (ide-cel; bb2121) for the treatment of adult multiple myeloma patients who have received at least 3 prior treatments, based on data from the pivotal Phase 2 KarMMa trial (NCT03361748).
In addition, potentially by 2021, we may have these BCMA-targeted CAR-T cell therapies available in standard practice. Targets other than BCMA are being investigated such as GPRC5D and FcRH which are currently under development for bispecific approaches.
